Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 12Phase NA 8Phase 4 4Phase 2/3 4Phase 1/2 4Phase 1 2

Status

Completed 7Unknown 4Recruiting 3Terminated 2Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 3Hydatidiform Mole 1Gestational Trophoblastic Disease 1Breast Diseases 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Letrozole × Clear all
NCT05523609 2023-12-01

Vitamin D and Calcium Supplementation in Breast Cancer

Tanta University

Phase 2/3 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT05203562 2022-07-12

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Zagazig University

Phase 2/3 Unknown
200 enrolled
Gynecologic

Hydatidiform Mole, Gestational Trophoblastic Disease

NCT03507465 2018-04-25

Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer

Guangdong Provincial People's Hospital

Phase 2/3 Unknown
290 enrolled
Breast

Breast Neoplasms

NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Shandong Cancer Hospital and Institute

Phase 2/3 Unknown
200 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡